Evidence map›Paper›PMID 23660594›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2013

Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells.

Jordan V Li, Christopher D Chien, Jason P Garee, Jianming Xu, Anton Wellstein, Anna T Riegel

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. International journal of molecular sciences · 2019
    Review
  9. Article
  10. Foxg1 localizes to mitochondria and coordinates cell differentiation and bioenergetics.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jordan V LiDepartment of Pharmacology, Lombardi Cancer Center, Georgetown University, Research Building E307, 3970 Reservoir Road Northwest, Washington, DC 20007-2197, USA.
Christopher D Chien
Jason P Garee
Jianming Xu
Anton Wellstein
Anna T Riegel
Georgetown University · USBaylor College of Medicine · USGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
Role of AIB1 in malignant progressionR01CA113477 · NCI · GEORGETOWN UNIVERSITY · PI RIEGEL, ANNA TATE · 2005 to 2015
$2.9M
NCI NIH HHS CA051008NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA113477NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

The oncogene nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is a transcriptional coactivator that is overexpressed in various types of human cancers. However, the molecular mechanisms controlling AIB1 expression in the majority of cancers remain unclear. In this study, we identified a novel interacting protein of AIB1, forkhead-box protein G1 (FoxG1), which is an evolutionarily conserved forkhead-box transcriptional corepressor. We show that FoxG1 expression is low in breast cancer cell lines and that low levels of FoxG1 are correlated with a worse prognosis in breast cancer. We also demonstrate that transient overexpression of FoxG1 can suppress endogenous levels of AIB1 mRNA and protein in MCF-7 breast cancer cells. Exogenously expressed FoxG1 in MCF-7 cells also leads to apoptosis that can be rescued in part by AIB1 overexpression. Using chromatin immunoprecipitation, we determined that FoxG1 is recruited to a region of the AIB1 gene promoter previously characterized to be responsible for AIB1-induced, positive autoregulation of transcription through the recruitment of an activating, multiprotein complex, involving AIB1, E2F transcription factor 1, and specificity protein 1. Increased FoxG1 expression significantly reduces the recruitment of AIB1, E2F transcription factor 1 and E1A-binding protein p300 to this region of the endogenous AIB1 gene promoter. Our data imply that FoxG1 can function as a pro-apoptotic factor in part through suppression of AIB1 coactivator transcription complex formation, thereby reducing the expression of the AIB1 oncogene.

Indexed as

ApoptosisTranscription, GeneticBreast NeoplasmsDown-RegulationE2F1 Transcription FactorFemaleForkhead Transcription FactorsGene Expression Regulation, NeoplasticHEK293 CellsHumansMCF-7 CellsModels, BiologicalNerve Tissue ProteinsNuclear Receptor Coactivator 3Promoter Regions, GeneticProtein BindingE2F1 protein, humanE2F1 Transcription FactorForkhead Transcription FactorsFOXG1 protein, humanNCOA3 protein, humanNerve Tissue ProteinsNuclear Receptor Coactivator 3Repressor ProteinsSp1 Transcription Factor

Identifiers

PMID23660594
PMCPMC3706839
OpenAlexW2086212976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.